Shares of Sun Pharmaceutical Industries (Sun Pharma) have climbed 16% over the past 10 trading days, hitting a 52-week high of ₹1,885 amid a generally weak market. This surge follows the announcement on April 27, 2026, that the company will acquire Organon, a global healthcare firm, for $11.75 billion. The deal is projected to significantly enhance Sun Pharma's global presence, potentially positioning it among the top 25 pharmaceutical companies worldwide with a pro-forma revenue of $12.4 billion. Analysts expect the acquisition to bolster Sun Pharma's leadership in Women's Health and Biosimilars, while also expanding its innovative medicine portfolio. The acquisition is anticipated to generate cost synergies of approximately $350 million through improved procurement and manufacturing efficiencies. Brokerages have responded positively, with target prices for Sun Pharma's shares being revised upward, reflecting strong confidence in the company's future growth post-acquisition.